Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

488 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Conducting a phase III clinical trial in children during the COVID- 19 pandemic: Experience and lessons learnt from a clinical research facility of Nepal.
Chapagain RH, Maharjan J, Adhikari S, Thapa P, Kunwar K, Giri BR, Shrestha NJ, Shrestha AK, Shrestha SK, Tamang SM, Cho H, Park EL, Lee J, Lee J, Kim DR, Yang JS, Saluja T, Wartel A, Lynch J, Song KR. Chapagain RH, et al. Among authors: kim dr. Hum Vaccin Immunother. 2023 Aug 1;19(2):2239680. doi: 10.1080/21645515.2023.2239680. Hum Vaccin Immunother. 2023. PMID: 37539816 Free PMC article. Review.
An Open Label Non-inferiority Trial Assessing Vibriocidal Response of a Killed Bivalent Oral Cholera Vaccine Regimen following a Five Year Interval in Kolkata, India.
Kanungo S, Desai SN, Saha J, Nandy RK, Sinha A, Kim DR, Bannerjee B, Manna B, Yang JS, Ali M, Sur D, Wierzba TF. Kanungo S, et al. Among authors: kim dr. PLoS Negl Trop Dis. 2015 May 29;9(5):e0003809. doi: 10.1371/journal.pntd.0003809. eCollection 2015 May. PLoS Negl Trop Dis. 2015. PMID: 26023778 Free PMC article. Clinical Trial.
A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines.
Baik YO, Choi SK, Olveda RM, Espos RA, Ligsay AD, Montellano MB, Yeam JS, Yang JS, Park JY, Kim DR, Desai SN, Singh AP, Kim IY, Kim CW, Park SN. Baik YO, et al. Among authors: kim iy, kim cw, kim dr. Vaccine. 2015 Nov 17;33(46):6360-5. doi: 10.1016/j.vaccine.2015.08.075. Epub 2015 Sep 5. Vaccine. 2015. PMID: 26348402 Clinical Trial.
Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children.
Capeding MR, Teshome S, Saluja T, Syed KA, Kim DR, Park JY, Yang JS, Kim YH, Park J, Jo SK, Chon Y, Kothari S, Yang SY, Ham DS, Ryu JH, Hwang HS, Mun JH, Lynch JA, Kim JH, Kim H, Excler JL, Sahastrabuddhe S. Capeding MR, et al. Among authors: kim yh, kim h, kim dr, kim jh. Vaccine. 2018 Jun 18;36(26):3794-3801. doi: 10.1016/j.vaccine.2018.05.038. Vaccine. 2018. PMID: 29776750 Free PMC article. Clinical Trial.
Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report.
Capeding MR, Alberto E, Sil A, Saluja T, Teshome S, Kim DR, Park JY, Yang JS, Chinaworapong S, Park J, Jo SK, Chon Y, Yang SY, Ham DS, Ryu JH, Lynch J, Kim JH, Kim H, Excler JL, Wartel TA, Sahastrabuddhe S. Capeding MR, et al. Among authors: kim h, kim dr, kim jh. Vaccine. 2020 Jun 9;38(28):4476-4483. doi: 10.1016/j.vaccine.2019.09.074. Epub 2019 Oct 1. Vaccine. 2020. PMID: 31585725 Free PMC article. Clinical Trial.
Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study.
Capeding MR, Sil A, Tadesse BT, Saluja T, Teshome S, Alberto E, Kim DR, Park EL, Park JY, Yang JS, Chinaworapong S, Park J, Jo SK, Chon Y, Yang SY, Ryu JH, Cheong I, Shim KY, Lee Y, Kim H, Lynch JA, Kim JH, Excler JL, Wartel TA, Sahastrabuddhe S. Capeding MR, et al. Among authors: kim h, kim dr, kim jh. EClinicalMedicine. 2020 Sep 9;27:100540. doi: 10.1016/j.eclinm.2020.100540. eCollection 2020 Oct. EClinicalMedicine. 2020. PMID: 33150320 Free PMC article.
Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
Kumar Rai G, Saluja T, Chaudhary S, Tamrakar D, Kanodia P, Giri BR, Shrestha R, Uranw S, Kim DR, Yang JS, Park IY, Kyung SE, Vemula S, Reddy E J, Kim B, Gupta BP, Jo SK, Ryu JH, Park HK, Shin JH, Lee Y, Kim H, Kim JH, Mojares ZR, Wartel TA, Sahastrabuddhe S. Kumar Rai G, et al. Among authors: kim h, kim b, kim dr, kim jh. Lancet Infect Dis. 2022 Apr;22(4):529-540. doi: 10.1016/S1473-3099(21)00455-2. Epub 2021 Dec 20. Lancet Infect Dis. 2022. PMID: 34942090 Free PMC article. Clinical Trial.
Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose.
Capeding MR, Tadesse BT, Sil A, Alberto E, Kim DR, Park EL, Park JY, Yang JS, Eluru JR, Jo SK, Kim H, Yang SY, Ryu JH, Park H, Shin JH, Lee Y, Kim JH, Mojares ZR, Wartel TA, Sahastrabuddhe S. Capeding MR, et al. Among authors: kim h, kim dr, kim jh. NPJ Vaccines. 2022 Jan 27;7(1):12. doi: 10.1038/s41541-022-00434-8. NPJ Vaccines. 2022. PMID: 35087084 Free PMC article.
488 results